Search - tctmd.com

Displaying 601 - 620 of 795

Sort: Relevancy | Date

Presentation TCT 2013

Biodegradable-Polymer Drug-Eluting Stents versus Bare Metal Stents versus Durable-Polymer Drug-Eluting Stents : A Systematic Review and Bayesian Approach Network Meta-Analysis

Presenter: Si-Hyuck Kang

October 29, 2013

Presentation TCT 2013

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Presenter: Laura Mauri

October 28, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

Presenter: David Antoniucci

October 28, 2013

Presentation TCT 2013

The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results

Presenter: Martin Leon

October 28, 2013

Presentation TCT 2013

Synthesis of the ISAR Clinical Trials Comparing Different Stents in Different Settings

Presenter: Adnan Kastrati

October 28, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II

Presenter: Gregg Stone

October 28, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

Presenter: Young-Hak Kim

October 28, 2013

Presentation TCT 2013

Dedicated Bifurcation Stents for the Left Main: Experience with Axxess, Tryton and Others

Presenter: Eulogio Garcia

October 28, 2013

Presentation TCT 2013

Contra Position: Dedicated Bifurcation Stents are a Historical Cconcept and are No Longer Needed!

Presenter: Bernard Chevalier

October 28, 2013

Presentation TCT 2013

Case #2: A Complex Bifurcation: Dedicated Stent, Planned 2 Stents or Provisional Stent strategy?

Presenter: Gregory Pavlides

October 28, 2013

Presentation TCT 2013

A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon Plus Bare Metal Stents vs. Paclitaxel-Eluting Stents for De Novo Coronary Lesions

Presenter: Piotr Buszman

October 28, 2013

Presentation TCT 2013

SFA Stents Can No Longer Be Justified on an Outcomes or Cost Basis!

Presenter: Thomas Zeller

October 27, 2013

Presentation TCT 2013

Management of Patients with Atrial Fibrillation and Stents

Presenter: Neal Kleiman

October 27, 2013

Presentation TCT 2013

Bare Metal and Drug-Eluting Stents: Indications, Outcomes, Complications

Presenter: Sahil Parikh

October 27, 2013

Presentation

Risk of MACE Following Noncardiac Surgery in Patients with Coronary Stents

Presenter: Mary T. Hawn

October 08, 2013

Presentation Scripps 2013

Complex 3 Vessel Disease and Unprotected Left Main PCI: What Is the Role of Stents in the Post

Presenter: Paul S. Teirstein

October 04, 2013

Presentation Scripps 2013

Drug-eluting Stents 2013: Current Data, Future Advances

Presenter: James B. Hermiller, Jr.

October 03, 2013

Presentation

Meta-analysis of Everolimus-Eluting vs. Paclitaxel-Eluting Stents in CAD

Presenter: George D. Dangas

September 16, 2013

Presentation SOLACI 2013

Can We Still Improve DES Technology?: Newer Bioresorbable Polymer & Polymer-Free Stents

Presenter: Yaron Almagor

July 26, 2013

Advertisement

Biodegradable-Polymer Drug-Eluting Stents versus Bare Metal Stents versus Durable-Polymer Drug-Eluting Stents : A Systematic Review and Bayesian Approach Network Meta-Analysis

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results

Synthesis of the ISAR Clinical Trials Comparing Different Stents in Different Settings

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

Dedicated Bifurcation Stents for the Left Main: Experience with Axxess, Tryton and Others

Contra Position: Dedicated Bifurcation Stents are a Historical Cconcept and are No Longer Needed!

Case #2: A Complex Bifurcation: Dedicated Stent, Planned 2 Stents or Provisional Stent strategy?

A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon Plus Bare Metal Stents vs. Paclitaxel-Eluting Stents for De Novo Coronary Lesions

SFA Stents Can No Longer Be Justified on an Outcomes or Cost Basis!

Management of Patients with Atrial Fibrillation and Stents

Bare Metal and Drug-Eluting Stents: Indications, Outcomes, Complications

Risk of MACE Following Noncardiac Surgery in Patients with Coronary Stents

Complex 3 Vessel Disease and Unprotected Left Main PCI: What Is the Role of Stents in the Post

Drug-eluting Stents 2013: Current Data, Future Advances

Meta-analysis of Everolimus-Eluting vs. Paclitaxel-Eluting Stents in CAD

Can We Still Improve DES Technology?: Newer Bioresorbable Polymer & Polymer-Free Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content